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Abstract 
Bone morphogenetic protein 7 (BMP7) has been reported to confer renoprotective effects in 
acute and chronic kidney disease models, but its potential role in type 2 diabetic nephropathy 
remains unknown. In cultured human proximal tubular epithelial cells (PTECs), exposure to 
advanced glycation end products (AGEs) induced overexpression of intercellular adhesion 
molecule 1 (ICAM1), monocyte chemoattractant protein 1 (MCP1), interleukin 8 (IL-8) and 
interleukin 6 (IL-6), involving activation of p44/42 and p38 mitogen-activated protein kinase 
(MAPK) signaling. BMP7 dose-dependently attenuated AGE-induced upregulation of ICAM1, 
MCP1, IL-8 and IL-6 at both mRNA and protein levels. Moreover, BMP7 suppressed 
AGE-induced p38 and p44/42 MAPK phosphorylation and reactive oxygen species production 
in PTECs. Compared with vehicle control, uninephrectomized db/db mice treated with BMP7 
for 8 weeks had significantly lower urinary albumin-to-creatinine ratio (3,549±816.2 μg/mg vs. 
8,612±2,037 μg/mg, p=0.036), blood urea nitrogen (33.26±1.09 mg/dL vs. 37.49±0.89 mg/dL, 
p=0.006), and renal cortical expression of ICAM1 and MCP1 at both gene and protein levels. 
In addition, BMP7-treated animals had significantly less severe tubular damage, interstitial 
inflammatory cell infiltration, renal cortical p38 and p44/42 phosphorylation, and lipid 
peroxidation. Our results demonstrated that BMP7 attenuates tubular pro-inflammatory 
responses in diabetic kidney disease by suppressing oxidative stress and multiple inflammatory 
signaling pathways including p38 and p44/42 MAPK. Its potential application as a therapeutic 
molecule in diabetic nephropathy warrants further investigation. 
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INTRODUCTION 
Diabetic nephropathy (DN) is the leading cause of end stage renal disease (ESRD) in most 
developed countries [1], and over 90% are due to type 2 diabetes. Although the precise 
pathogenetic mechanisms of type 2 diabetes have yet to be worked out, emerging evidence 
strongly suggests an inflammatory component involving activation of the circulating 
complement system and pro-inflammatory chemokines and cytokines [2], which are closely 
associated with the development and progression of DN [3]. Despite current recommendations 
of full RAS blockade and stringent glycemic, lipid, and blood pressure control, the residual risk 
of renal progression in DN has remained high. Short of a specific protocol, it is conceivable 
that any therapeutic approach that intervene the downstream tubulotoxic effects of T2DN is a 
promising alternative for renoprotection. Anti-inflammatory concept open a new door for DN 
treatment, pre-clinical trials and clinical trials have been launched targeted specific cytokines, 
such as IL-1β specific antibody [4, 5], TNF blocker [6], or modulating pro-inflammatory 
pathways [7-9]. Although the results of some of these clinical trials are promising, their overall 
clinical utilities are still limited [2]. Therefore, the development of additional therapeutic 
interventions remains a major priority. 
Bone morphogenetic protein 7 (BMP7) is a homodimeric protein that belongs to the 
TGF-β superfamily. BMP7 is vital for kidney development and is only selectively expressed in 
several adult organs including kidney [10]. BMP7 has been reported to be down regulated 
under several disease conditions [11-13], and administration of exogenous BMP7 has been 
shown to inhibit injury in acute or chronic kidney disease [14-16]. For diabetic nephropathy, 
BMP7 has been reported to preserve podocytes [17] and rescue type1 DN [18-21]. However, 
most of these studies mainly focused on the anti-fibrotic role of BMP7. Gould et al. reported 
that BMP7 suppressed TNF-alpha induced pro-inflammatory cytokines in PTECs [22], and 
Wang et al. also reported that BMP7 reduced tubulointerstitium macrophage infiltration in 
STZ-induced DN [21], suggesting an anti-inflammatory role of BMP7. 
Tubular damage is a major feature of DN [23-27], and tubulointerstitium lesions are 
predictive of renal function and prognosis in DN patients [28]. We recently found that different 
kinds of AGEs caused differential effects on renal tubular cell inflammation [29, 30], however, 
whether BMP7 can prevent AGE-induced kidney injuries or preserve kidney function in type 2 
DN remains unknown. Herein, we explored the potential anti-inflammatory role of BMP7 in 
AGE-induced tubular injury in vitro and in a murine model of type 2 DN. 
 
METHODS AND MATERIALS 
 
Cell culture 
Primary human renal proximal tubular epithelial cells (PTECs) were purchased from Lonza 
(Walkersville, MD, USA). Cells were cultured in Renal Epithelial Cell Basal Medium (REBM) 
with supplemented growth factors and maintained at 37°C in 5% CO2 and 95% air. In all 
experiments, cells (from passage 2-4) were grown to 70~80% confluency and were arrested in 
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serum-free medium for 24 h before stimulation. Cells were stimulated with advanced glycation 
end products of human serum albumin (AGEs) (100 µg/ml, Sigma-Aldrich, St. Louis, MO) 
with or without BMP7 (100 ng/ml, R&D Systems, Minneapolis, MN). Inhibitors of p38 
(SB203580 10 μM), p44/42 MAPK (PD98059 25 μM) signalling pathways were added into the 
culture system, gene and protein level of different cytokines and chemokines were detected. 
Unless otherwise specified, PTECs were harvested at 3 h or 24 h after stimulation for gene and 
protein expression study respectively. 
 
Animal Model 
For in vivo study, genetically diabetic male db/db mice and their non-diabetic db/m littermates 
(The Jackson Laboratory, Bar Harbor, ME, USA) were used. All work with mice was approved 
by the Committee on the Use of Live Animals in Teaching and Research of The University of 
Hong Kong, and was performed in accordance with the NIH Guide for the Care and Use of 
Laboratory Animal.  
At age of 9 weeks, mice underwent uninephrectomy (Unx) or sham operation as described 
previously [32]. Briefly, a dorsal-ventral incision was made on the right side of the abdominal 
cavity in anaesthetized mice, the right renal pedicle was identified and ligated followed by 
carefully dissected out of the kidney. Then the abdominal wall and skin was sutured. 
Sham-operated mice were also anaesthetized and had their abdominal cut and right renal 
pedicle manipulated without ligation. The animals were then warmed in intensive care unit full 
recovery from anesthesia. Two weeks after operation, Unx and sham-operated mice were 
randomized into 4 groups (n=10~11 each): db/db sham group, Unx db/db vehicle group, Unx 
db/db BMP7 group and Unx db/m vehicle group and received BMP7 (300 µg/kg body weight) 
or equivalent volume of vehicle intraperitoneally every other day. After 8 weeks of treatment, 
all mice were sacrificed and the kidney were harvested, half of the kidney was snap frozen in 
liquid nitrogen and stored at -70°C for mRNA and protein extraction. The other half was fixed 
with 10% formalin and embedded in paraffin for histological study. Systolic blood pressure 
was measured by using a computerized tail cuff system (Visitech Systems, Cary, NC). 
Twenty-four hour urine samples were collected by metabolic cages. Serum was drawn and 
separated from the sub-mandibular vein at baseline and end point and stored at -70°C for 
further investigation. 
 
Total RNA extraction and real-time PCR 
Total RNA was extracted from the cultured cells and kidney cortical tissue using Trizol reagent 
(Invitrogen, Carlsbad, CA) and was reverse transcribed to cDNA with High Capacity cDNA 
Reverse Transcription Kits (Applied Biosystems, Foster City, CA, USA). Real-time PCR 
analysis was performed using SYBR green Master Mix (Applied Biosystems) according to the 
manufacturer’s instruction, the amplification was carried out in an ABI Prism 7500 sequence 
detection system (Applied Biosystems). The primer sequences used in both in vitro and in vivo 
studies were listed as Table 2. The relative quantification of cDNA in each sample was 
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normalized to β-actin cDNA and the data was analyzed by the SDS software (Applied 
Biosystems). Data were presented as relative fold change compared to the control. 
 
 
ELISA  
Pro-inflammatory cytokine expressions were measured in 24 h condition medium. ICAM1, 
MCP1, IL-8 and IL-6 protein levels were quantified using commercial kit (PeproTech, Rocky 
Hill, NJ) following the manufacturer's instructions. Renal cortical protein was extracted by 
using RIPA lysis buffer (Millipore, Bedford, USA), cortical MCP1 and ICAM1 levels were 
detected with mouse MCP1 and ICAM1 Duoset ELISA kit (R&D Systems,) respectively. 
 
Western blot analysis 
Growth-arrested PTECs were stimulated with AGEs (100 µg/mL) with or without BMP7 (100 
ng/mL) for 30 min. Cells were washed with PBS and then lysed with lysis buffer containing 
protease inhibitor (Sigma Aldrich) as previously described [33]. Total protein concentrations 
were determined by Pierce BCA method (Thermo Scientific, Rockford, USA). Equal amount of 
proteins were dissolved in loading buffer and denatured by boiling at 95°C for 10 min. Protein 
samples were run on 12% SDS-PAGE gel and transferred to PVDF membrane (Millipore). 
Membrane were blocked with 5% non-fat milk and incubated overnight with primary 
antibodies against phosphor-p38 MAPK (1:1000), p38 MAPK (1:2000), phosphor-p44/42 
(1:2000) and p44/42 (1:2000) (Cell Signaling Technology, Beverly, MA) in Tris-buffered 
saline with 0.1% Tween-20, and subsequently incubated with horseradish 
peroxidase-conjugated secondary antibodies (Dako, Carpinteria, CA) for 2 h. Reactions were 
visualized by using ECL plus chemiluminescence (GE Healthcare, Buckinghamshire, UK) with 
ChemiDoc XRS+ system (Bio-Rad, Hercules, CA). Density of bands were quantified by 
bundled ChemiDoc software and normalized by actin level. 
  
Detection of intracellular reactive oxygen species 
Intracellular reactive oxygen species (ROS) were measured using OxiSelectTM Intracellular 
ROS Assay Kit (Cellbiolabs, San Diego, CA) according to the manufacturer's instruction. 
Briefly, PTECs were pretreated with DCFH-DA (dissolved in DMEM) for 1 h, cells were 
washed and stimulated with plain medium or medium with AGEs, AGEs with BMP7 and H2O2  
for 1 h,  then were lysed for fluorescence measurement using FLUOStar Omega plate reader 
(BMG labtech, Germany) for excitation at 485 nm and emission at 520 nm. 
PTECs were seeded in 8-well chamber slides (Nunc Lab-Tek II, Thermo Scientific, USA) and 
growth-arrested for 24 h until 80% confluence. Cells then treated with AGEs, AGEs with 
BMP7, H2O2 (500 µM) as positive control and plain medium as normal control. After 1 h 
incubation, cells were washed with PBS and incubated with an oxidative stress indicator 
CM-H2DCFDA (500 µM, Invitrogen) for 45 min, then cells were washed with PBS and fixed 
with 4% paraformaldehyde for 15 min. Slides were mounted with Vectashield and  
6 
4',6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, USA) and visualized 
under fluorescence microscope. 
 
Quantitation of MDA level in renal tissue 
Lipid peroxidation of renal cortical tissue was determined by using OxiSelectTM TBARS Assay 
Kit (Cell Biolabs) according to the manufacturer’s instruction. Tissue lysate or MDA standard 
was incubated with SDS lysis solution for 5 min at room temperature; Thiobarbituric acid 
(TBA)  was added to the mixture and incubated at 95°C for 60 min. Supernatant of the lysate 
was then transferred into 96-well plate and read for absorbance at 540 nM. Data was presented 
as fold change of MDA-TBA adduct compared with the db/db sham group. 
 
Biochemical analysis of serum and urine specimens 
Urine albumin concentration was determined by mouse albumin ELISA kit (Bethyl 
Laboratories, Montgomery, TX), Urine creatinine, serum blood urea nitrogen (BUN) and blood 
glucose concentrations were measured by enzymatic method using commercially available test 
kits (Stanbio Laboratory, Boerne, TX). 
 
Histological examination and immunohistochemistry 
Periodic Acid-Schiff (PAS) staining (Sigma-Aldrich) was performed in 4 µm paraffin sections 
following the manufacturer's protocol. Glomerular and tubulointerstitial damage of kidney were 
quantified by Image Pro Plus Software 5.0 (Media Cybernetics, Silver Spring, USA), thirty 
fields in the cortex were randomly selected to collect the integrated optical density of lesions 
and area of the field. Data were presented as the average integrated optical density per area 
(IOD/Area) value.  
Immunohistochemistry was performed to detect macrophage cell marker F4/80. Four 
micrometers paraffin sections were deparaffinized and rehydrated through a descending ethanol 
gradient. Enzymatic digestion with protease protease K was used for antigen retrieval. 
Sections were incubated with anti-F4/80 antibody (1:50, Serotec, Oxford, UK) at 4°C overnight 
and subsequently HRP-conjugated secondary antibodies. Positive staining was visualized as 
brown color using DAB substrate (Dako). The number of F4/80+ cells was counted in 20 
randomly selected high-power cortical fields per kidney section and expressed as the average 
number of cells per field (number/HPF). 
 
Statistical analysis 
All data were presented as means ± standard error unless otherwise specified. Statistical 
analysis was performed using GraphPad Prism 5.0 for Windows (GraphPad Software Inc., San 
Diego, USA). Difference between multiple groups was analyzed by one-way ANOVA with 
Bonferroni’s intergroup comparison. p < 0.05 was considered statistically significant. 
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RESULTS 
 
BMP7 attenuated AGE-induced pro-inflammatory response in PTECs 
Real-time PCR showed that AGEs (100 μg/mL) superinduced expression of ICAM1 and IL-8 
over equivalent doses of HSA in PTECs, and BMP7 dose-dependently attenuated this response. 
The optimal dosage of BMP7 at 100 ng/mL was used in this study (Figure 1).  
The anti-inflammatory effect of BMP7 was confirmed by the expression profile of other 
cytokines. Real-time PCR and ELISA results revealed that BMP7 reduced AGE-induced 
overexpression of monocyte chemoattractant protein-1 (MCP1), Interleukin 8 (IL-8), 
Intercellular Adhesion Molecule 1 (ICAM1), and Interleukin 6 (IL-6) in PTECs in both gene 
and protein levels. (Figure 2) 
 
AGEs induced pro-inflammatory responses through multiple signaling pathways in PTECs  
Pretreatment of PTECs with MAPK inhibitors attenuated AGE-induced cytokine expressions. 
Inhibition of p38 signalling with SB203580 reduced overexpression of IL-8 and MCP1, and 
inhibition of p44/42 signalling with PD98059 reduced upregulation of IL-8 and ICAM1 (Figure 
3). Suggested AGEs induced pro-inflammatory responses through multiple signaling pathways. 
 
BMP7 suppressed AGE-induced phosphorylation of p38 and p44/42 protein  
To test whether anti-inflammatory effect of BMP7 is mediated through MAPK pathways, 
phosphorylation of p38 and p44/42 protein was determined by western blot analysis. Figure 4 
showed that AGEs increased p38 and p44/42 phosphorylation in PTECs, whereas co-incubation 
with BMP7 suppressed their phosphorylation significantly. This result suggests that BMP7 
attenuates AGE-induced pro-inflammatory responses through modulating p38 and p44/42 
MAPK signalling pathway. 
 
BMP7 attenuated AGE-induced reactive oxygen species (ROS) accumulation in PTECs  
Considering that AGEs may induce cellular oxidative stress, also, increased ROS production  
may lead to the activation of p44/42 or p38 MAPK [34],  ROS formation was measured in 
AGE-stimulated PTECs. Immunofluorescence study showed that after stimulation with AGEs 
for 1 h, ROS accumulation was significantly higher than the medium control, AGEs 
co-incubated with BMP7 reduced ROS formation in PTECs. Quantitative intracellular ROS 
measurement by OxiSelectTM Intracellular ROS Assay Kit also showed a 50% increase in ROS 
formation in AGE-stimulated cells and it was abolished by co-incubated with BMP7 (Figure 5).  
 
BMP7 preserved kidney function and kidney morphology in diabetic kidney 
At the age of 9 weeks, diabetic db/db mice have already developed hyperglycemia (blood 
glucose) obesity (body weight), manifestation of albuminuria (UACR) and reduction of kidney 
function (BUN) compared with non-diabetic db/m mice as shown in Table 1. BMP7 did not 
affected blood glucose level and systolic blood pressure throughout the experiment. Unx db/m 
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mice showed a slightly increase in systolic blood pressure and serum BUN (p<0.05) after 8 
weeks of treatment, however Unx did not show any effect on these parameters on db/db mice. 
As reported in our previous study [32], Unx markedly exaggerated UACR and serum BUN 
level in db/db mice compared with sham-operated db/db mice in this study. Average UACR of 
Unx-db/db vehicle group was 2 fold higher than Unx db/db mice received BMP7 injection 
(8612±2037 μg/mg vs. 3549±816.2 μg/mg, p=0.036). Serum BUN of Unx-db/db mice treated 
with BMP7 showed significantly lower level (33.26±1.09 mg/dL vs. 37.49±0.89 mg/dL, 
p=0.006) when compared with Unx-db/db vehicle group.  
Morphologically, sham-operated db/db mice displayed mild glomerular and 
tubulointerstitial damage, while Unx-db/db mice developed glomerular hypertrophy, nodular 
glomerulosclerosis and severe tubular damage (tubular dilation and atrophy), and such 
glomerular and tubular damages were partially abrogated by BMP7 treatment (Figure 6).  
 
BMP7 attenuated renal cortical inflammation and macrophage infiltration in diabetic mice 
To explore whether exogenously administration of BMP7 confers similar anti-inflammatory 
effect in diabetic kidney as shown in the in vitro study, cortical expression of pro-inflammatory 
cytokines ICAM1 and MCP1 were examined by real-time PCR and ELISA. Diabetes caused 
overexpression of MCP1 and ICAM1 in Unx-db/db mice in both gene and protein levels when 
compared to Unx-db/m control mice (Figure 7). A significant increase in macrophage 
infiltration in the tubulointerstitium was also observed in parallel with the upregulation of 
MCP1 and ICAM1 in Unx diabetic kidney (Figure 8). Administration of BMP7 reduced renal 
cortical expression of MCP1 and ICAM1 at 40% and 16.7% respectively when compared to 
Unx-db/db vehicle group.  
 
BMP7 suppressed p38 and p44/42 MAPK activation in DN 
To explore the possible molecular mechanisms of BMP7 in modulating diabetic kidney 
inflammation, Western blot analysis demonstrated a significantly increase in cortical p38 and 
p44/42 MAPK phosphorylation in Unx-db/db mice injected with vehicle than mice received 
sham-operation. Treatment of BMP7 significantly suppressed 40% of p38 and 60% of p44/42 
MAPK phosphorylation, suggesting that BMP7 exerts in vivo anti-inflammatory effect by 
modulating these MAPK pathways in diabetic kidney (Figure 9). 
 
BMP7 reduced cortical lipid peroxidation in diabetic kidney 
The degree of oxidative stress in renal cortex was determined by measuring the end product of 
lipid peroxidation. Aldehydic secondary products malondialdehyde (MDA) in the kidney 
reacted with thiobarbituric acid (TBA) to form the MDA-TBA adduct, which can be measured 
colorimetrically. Lipid peroxidation was significantly higher in Unx-db/db vehicle group than 
the other groups (db/db sham, Unx-db/db BMP7 and Unx-db/m groups, p<0.01.). 
Administration of BMP7 reduced 20% of MDA formation in diabetic kidney (Figure 10). 
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DISCUSSION 
BMP7 has been demonstrated to have profound anti-fibrotic effects in the diabetic kidney, as 
demonstrated mainly in STZ-induced animal models, reflecting type 1 diabetes. Herein, we 
showed for the first time that BMP7 also possesses anti-inflammatory effects in renal tubular 
epithelial cells and in a model of type 2 diabetic nephropathy.  
In vitro, BMP7 attenuated AGE-induced tubular inflammation through suppressing 
multiple pathways including p38 and p44/42 MAPK. A strength of these in vitro data stems 
from the fact that they were derived using primary human proximal tubular epithelial cells that 
offer a good viable model for the proximal tubule epithelia. Although immortalized 
human-transformed cell lines have been extensively used and are extremely useful for these 
purposes, they exhibit limitations in their phenotypic resemblance to primary PTECs in culture 
[31]. In vivo, we demonstrated that BMP7 restored renal function and abrogated cortical 
inflammation in T2DN. Finally, BMP7 exerted anti-oxidative effects both in vitro and in vivo. 
Our findings are in line with previous observations in certain non-diabetes-related 
investigations. For instance, BMP7 repressed TNF-α induced pro-inflammatory chemokines 
and cytokines in primary human PTECs [22]. Lee et al. found that BMP7 significantly 
inhibited constitutive and IL1-β induced MCP1 expression in mesangial cells by modulating 
the JNK/AP1 pathway [35]. Administration of BMP7 decreased IL-1β production in an 
inflammatory arthritis rat model [36]. Our previous study also demonstrated that BMP7 
suppressed polymeric IgA induced TNF-α overexpression [37]. In diabetes, BMP7 reduced 
monocyte/macrophage infiltration in a STZ-induced diabetic rat model [21]. All these data 
suggested BMP7 conferred anti-inflammatory effect both in vitro and in vivo. It is likely that 
AGEs induce pro-inflammatory chemokine and cytokine overexpression by activating multiple 
intracellular signaling pathways, as the inhibition of a single signal transduction pathway could 
only suppress the expression of certain pro-inflammatory factors or even induced the 
expression of other factors (data not shown). Our in vivo results using db/db animals also 
revealed inhibition of p38 and p44/42 signaling pathways and their downstream genes by 
exogenous BMP7. So we believe BMP7 reduced various pro-inflammatory factors in 
AGE-induced tubular inflammation, mostly because BMP7 simultaneously suppressed multiple 
signaling pathways including the p38 and p44/42 MAPK. 
In addition to its action on the renal tubules, BMP7 may also exert notable glomerular 
effects in the context of diabetic nephropathy. In vitro, BMP7 ameliorated glucose–induced 
oxidative stress via inhibition of PKC, JNK phosphorylation and c-jun activation in rat 
mesangial cells [38], and reduced apoptosis by blocking HG-mediated caspase-3 overactivity in 
podocytes [17]. In addition, treatment with BMP7 restored synaptopodin and podocin 
expression in mouse podocytes exposed to HG [39]. In vivo, transgenic expression of human 
BMP7 in STZ-induced diabetic mice reduced glomerulosclerosis, interstitial collagen, 
albuminuria, podocyte dropout and increased nephrin levels compared with wild type animals 
[18]. In STZ-induced diabetic CD1 mice with renal lesions resembling human DN, BMP7 
inhibited glomerular hypertrophy and glomerulosclerosis, though it was most effective in 
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ameliorating tubular inflammation and tubulointerstitial fibrosis [19]. Also in STZ-induced 
diabetic C57Bl/6J CTGF+/- mice, there was increased phosphorylation of the BMP signal 
transduction proteins Smad1/5 and expression of the BMP target gene leading to reduced 
glomerular basement membrane thickening and albuminuria compared with CTGF+/+ mice, 
suggesting a pathogenetic role of CTGF in BMP signaling in DN [20]. Finally, BMP7 partially 
restored renal function, reduced albuminuria, and improved glomerular histology toward 
normal in STZ-induced diabetic rats [21]. 
Advanced glycation and oxidative stress are 2 key players in the pathogenesis of diabetic 
nephropathy [40]. Oxidative stress is induced by multiple pathways in diabetes. Hyperglycemia 
causes excessive ROS synthesis by direct autoxidation during the formation of AGEs and by 
inducing mitochondrial dysfunction [41]. Experimental studies showed that AGEs can further 
increase ROS generation through AGE receptor (RAGE) by stimulating NAD(P)H oxidase 
activity [42] and that AGE-induced oxidative stress is attenuated by NADPH oxidase inhibitor 
in human endothelial cells [43]. Oxidative stress in diabetes may also be enhanced by a change 
in antioxidant defence. There is evidence suggesting that AGEs decrease the enzyme activities 
of SOD and catalase [44] and altered activities of these enzymes are also observed in diabetic 
animal models. Hence, persistent hyperglycemia and oxidative stress enhance AGEs formation, 
thus setting up a vicious cycle of auto-amplification culminating in cell injury. Indeed, BMP7 
has been shown to attenuate ROS generation in high glucose stimulated rat mesangial cells [38] 
as stated above. Here, we showed for the first time that BMP7 not only attenuated oxidative 
stress in HG-exposed mesangial cells, but also reduced ROS formation in AGE-stimulated 
PTECs, in addition to its anti-inflammatory action. Moreover, BMP7 reduced lipid 
peroxidation in the diabetic kidney, substantiating the anti-oxidative effects of BMP7 in vivo. 
Mechanistically, we found BMP7 attenuated ROS formation and suppressed p38 and p44/42 
phosphorylation. This is not surprising considering that ROS induced activation of ERK and 
p38 MAPK [34]. Whether BMP7 modulates the expression of pro-inflammatory cytokines 
directly or indirectly through ROS generation requires further investigation. 
Although a large body of evidence points to an anti-fibrotic role of BMP7 [14, 45-47], 
mostly stating that BMP7 counteracts the profibrotic effects of TGF-β in several disease models 
[46], there exists opposite views. For instance, Dudas et al. reported that BMP7 failed to 
attenuate TGF-β induced epithelial-to-mesenchymal transition in human PTECs [48], in which 
cells cultured with BMP7 alone displayed increased vimentin, CTGF or even TGF-β expression. 
Interestingly, we also found that PTECs stimulated with BMP7 had significantly increased 
CTGF, type I collagen and reduced E-cadherin gene expression. As our mouse model did not 
develop notable renal fibrosis, we did not observe significant differences of pro-fibrotic 
markers in different diabetic groups. In addition, Masson Trichrome staining or 
immunohistochemical staining of collagen I & V did not yield significant differences among 
the various diabetic groups (data not shown). Hence, although BMP7 may promote fibrosis in a 
single cell type in a culture system, it is possible that its overall effects in vivo are the results of 
interactions between different resident and infiltrating cells, which is beyond the scope of this 
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study. Nevertheless, the anti-fibrotic role of BMP7 in T2DN warrants further investigation. 
 
CLINICAL PERSPECTIVES 
ESRD from type 2 DN imposes a heavy burden on most healthcare systems in the developed 
world, but therapeutic approaches to delay or prevent its occurrence are very limited. Diabetic  
tubulopathy has recently been shown to play a significant role in intrarenal inflammation 
during DN. BMP7 ameliorates diabetic tubulopathy by suppressing inflammatory and oxidative 
stress responses both in cultured renal tubular cells exposed to advanced glycation end products  
and in diabetic db/db mice. It therefore has the potential of being developed into an 
anti-inflammatory and anti-oxidative agent for the treatment of type 2 diabetic kidney disease. 
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FIGURE LEGENDS 
Figure 1. BMP7 dose-dependently reduced AGE-induced tubular inflammation. A. PTECs 
stimulated with AGE (100 μg/mL) and co-incubated with increasing concentrations of BMP7 
(0-200 ng/mL) for 3 h.; B. PTECs were stimulated with same concentration (100 μg/mL) of 
AGE and HSA, co-incubated with or without BMP7 for 3 h. mRNA expression was determined 
by real-time PCR. *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 2. BMP7 attenuated AGE-induced pro-inflammatory response in PTECs. A. 
mRNA expression of MCP1, IL-8, ICAM1 and IL-6 in PTECs cultured with AGEs (100 
μg/mL), AGEs plus BMP7 (100 ng/mL) or BMP7 alone. Nil denotes medium control. mRNA 
were collected after 3 h of treatment. B. Secreted MCP1, ICAM1, IL-6 and IL-8 levels in 
culture supernatants, collected at 24 h and measured by ELISA respectively. 
 
Figure 3. AGE-induced PTECs expression of pro-inflammatory factors is mediated 
through multiple pathways. PTECs were pre-treated with p44/42 inhibitor (PD98059, 25 μM) 
or p38 inhibitor (SB203580, 10 μM) 30min before adding AGEs into the culture medium. 3h 
mRNA and 24h supernatants were collected for measurement. A. mRNA and protein changes in 
PTECs incubated with p44/42 inhibitor; B. mRNA and protein changes in PTECs incubated 
with p38 inhibitor. 
 
Figure 4. BMP7 suppressed phosphorylation of p38, p44/42 induced by AGEs. PTECs 
were treated with AGEs (100 μg/mL) or AGEs plus BMP7 (100 ng/mL) for 30min; Nil denotes 
medium control. Bars are means ± SD of three independent experiments. 
 
Figure 5. BMP7 attenuated AGEs induced reactive oxygen species (ROS) accumulation in 
PTECs. PTECs were cultured in chamber slides with A. plain medium, B. H2O2 500 μM as 
positive control, C. AGEs 100 μg/mL and D. AGEs 100 μg/mL plus BMP7 100 ng/mL for 1h. 
ROS generation was detected by immunofluorescence signals using a Leica microscope 
(Magnification: 100X); E. Quantitative data of green fluorescent signals. Results were obtained 
from three independent experiments, and data was presented as fold change of Integrated 
Optical Density (IOD) vs medium control, *p<0.05; F. Intracellular ROS quantified by 
OxiSelectTM Intracellular ROS Assay Kit. Data were from three independent experiments, and 
results presented as ROS concentration, **p<0.01. 
 
Figure 6. BMP7 improved renal morphology in diabetic kidney. Representative periodic 
acid-Schiff staining of the renal cortical sections in uninephrectomized db/m mice (A), 
sham-operated db/db mice (B), Unx-db/db vehicle-treated mice (C), and Unx-db/db 
BMP7-treated mice (D). Magnification 400X. E. Quantification of glomerular 
tubulointerstitium damage using ImagePro plus, and expressed as IOD /Area x 105. *p<0.05, 
**p<0.01. 
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Figure 7. BMP7 attenuated renal cortical inflammation. A. Renal cortical ICAM1 and 
MCP1 mRNA expression, determined by real-time PCR. B. Renal cortical protein levels of 
ICAM1 and MCP1, determined by ELISA and normalized by total protein levels of tissue 
lysates. *p<0.05, **p<0.01. 
 
Figure 8. BMP7 attenuated macrophage infiltration in diabetic mice. Representative renal 
cortical sections of F4/80 immunostaining in uninephrectomized db/m mice (A), sham-operated 
db/db mice (B), Unx-db/db vehicle-treated mice (C), and Unx-db/db BMP7-treated mice (D). 
Magnification 400X. E. Quantification presented as number of F4/80+ cells (red arrows) per 
high power field. *p<0.05.  
 
Figure 9. BMP7 suppressed p38 and p44/42 phosphorylation in diabetic mice. Renal 
cortical p38 and p44/42 phosphorylation was determined by Western blot and quantified by 
ChemiDoc software. Samples were randomly picked up in each group (db/db sham: 3/10, 
Unx-db/db BMP7: 5 /10, Unx-db/db vehicle: 5 /11, respectively). *p<0.05.  
 
Figure 10. BMP7 reduced cortical lipid peroxidation in diabetic kidney. Cortical levels of 
lipid peroxidation were determined using OxiSelectTM TBARS Assay Kit, and data was 
presented as fold change of MDA-TBA adduct compared with the db/db sham groups. 
**p<0.01.  
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Table 1. Physical and biochemical parameters of experimental animals (n=10-11 per group) 
Parameter 
db/m db/db 
Unx Sham+vehicle Unx+BMP7 Unx+vehicle 
Body 
weight (g) 
baseline 24.45±0.53* 41.1±0.92 40.16±0.85 39.77±0.45 
8 weeks 26.95±0.43* 49.58±1.59 50.85±2.22 46.02±1.30 
Blood 
glucose (mM) 
baseline 9.86±0.31* 16.35±1.33 16.51±1.27 16.89±1.66 
8 weeks 8.24±0.35* 26.59±0.90 26.48±2.36 27.44±1.70 
Systolic BP 
(mmHg) 
baseline 117.4±5.36 116.6±2.45 124.5±7.86 123.6±6.36 
8 weeks 130.7±5.15@ 119.9±11.29 120.0±9.79 124.8±13.10 
UACR 
(μg/mg) 
baseline 437.9±26.44* 4220±356.6 4395±830.7 4068±397.5 
8 weeks 404.3±57.14* 3371±1029& 3549±816.2# 8612±2037 
BUN 
(mg/dL) 
baseline 21.02±0.97* 31.82±1.99 33.32±2.17 35.14±1.35 
8 weeks 32.69±0.89@ 28.98±1.93& 33.26±1.09# 37.49±0.89 
Unx, uninephrectomy; *p<0.05 vs db/db animals, @p<0.05 vs baseline,#p<0.05 vs Unx-db/db vehicle group, 
&#p<0.05 vs Unx-db/db vehicle group. 
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Table 2. Primer sequences for real-time PCR 
Gene Species Accession number Primer sequence 
ICAM1 
Homo 
Sapiens 
NM_000201.2 
Forward-5’-GGC CTC AGT CAG TGT GA-3’ 
Reverse-5’-AAC CCC ATT CAG CGT CA-3’ 
IL-8 NM_000584.3 
Forward-5’-GTG CAG TTT TGC CAA GGA GT-3’ 
Reverse-5’-TAA TTT CTG TGT TGG CGC AG-3’ 
MCP1 NM_002982.3 
Forward-5’-GAT CTC AGT GCA GAG GCT CG-3’ 
Reverse-5’-TGC TTG TCC AGG TGG TCC AT-3’ 
IL-6 NM_000600.3 
Forward-5’-ATG AAC TCC TTC TCC ACA AG-3’ 
Reverse-5’-TGT CAA TTC GTT CTG AAG AG-3’ 
β-actin NM_001101.3 
Forward-5’- TGA CGT GGA CAT CCG CAA AG -3’ 
Reverse-5’- CTG GAA GGT GGA CAG CGA GG -3’ 
ICAM1 
Mus 
Musculus 
NM_010493.2 
Forward-5’-TGG CCT GGG GGA TGC ACA CT -3’ 
Reverse-5’-GGC TGT AGG TGG GTC CGG G -3’ 
MCP1 NM_011333.3 
Forward-5’-CTC TTC CTC CAC CAC CAT-3’ 
Reverse-5’- CTC TCC AGC CTA CTC ATT G-3’ 
β-actin NM_007393.3 
Forward-5’- TCC ATC ATG AAG TGT GAC GT -3’ 
Reverse-5’-GAG CAA TGA TCT TGA TCT TCA T-3’ 
Abbreviations: ICAM1: Intercellular Adhesion Molecule 1; MCP1: monocyte chemoattractant protein-1; IL-8: Interleukin 8; 
IL-6: Interleukin 6. 
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